News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Diffusion Pharmaceuticals seeks Wall Street investment while staying local

Al's Comment:

 This is an important trial.  In the phase 2 trial, on newly diagnosed GBM patients who only had biopsies - not subtotal resection or complete resection, they had "in patients with inoperable tumors, who demonstrated a 380 percent increase in survival at two years."

This is so important that I am including it in my presentation to the FDA next week as an example of a drug that needs to be approved quickly!


Posted on: 06/18/2017

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740